uploads///dog _

Analysts’ Ratings for Abaxis and Its Peers in February 2018

By

Mar. 1 2018, Updated 8:53 a.m. ET

Company overview

Incorporated in California, Abaxis (ABAX) develops, manufactures, and commercializes portable blood analysis systems that are used in a wide range of medical specialties in human or veterinary patient care.

These systems help clinicians rapidly measure blood constituents. The company has worldwide operations and operates in two business segments: the medical market and the veterinary market.

Article continues below advertisement

Analysts’ recommendations

Of the ten analysts covering Abaxis in February 2018, two analysts gave the stock “strong buy” ratings, six gave it “hold” ratings, and two gave it “sell” ratings. The mean rating for the stock was 2.8, and its target price was $63.7.

Peers’ ratings

All five of the analysts covering Angio Dynamics (ANGO) in February 2018 gave the stock “hold” ratings. The mean rating for the stock was 3, and its target price was $16.1.

Of the seven analysts covering Halyard Health (HYH) in February 2018, two analysts gave the stock “strong buy” ratings, four gave it “hold” ratings, and one gave it a “sell” rating. The mean rating for the stock was 2.57, and it had a target price of $47.7.

Of the 22 analysts covering Merck & Co. (MRK) in February 2018, six analysts gave the stock “strong buy” ratings, seven analysts gave it “buy” ratings, and nine analysts gave it “hold” ratings. The mean rating for the stock was 2.14 with a target price of $66.6.

In the next part of the series, we’ll take a look at Abaxis’s business segments.

Advertisement

More From Market Realist